MedTrace Logo

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

NCT07571824 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2026-05-28

No results posted yet for this study

Summary

The purpose of this research study is to compare the bioavailability and adhesion of a generic Selegiline transdermal system (TDS) against the marketed comparator (EMSAM®) in healthy volunteers. Systemic and local safety and tolerability will be also observed and evaluated.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

Selegiline TDS 6 mg/24 hours

Selegiline TDS 6 mg/24 hours

DRUG

EMSAM® TDS 6 mg/24 hours

EMSAM® TDS 6 mg/24 hours

Sponsors & Collaborators

  • Corium Innovations, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-23
Primary Completion
2026-06-29
Completion
2026-07-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07571824 on ClinicalTrials.gov